癌におけるTRIB3-MYC軸をターゲットにする:メカニズム的洞察と治療的破壊戦略
PubMedで要約を見る
まとめ
この要約は機械生成です。トリブルズ偽キナーゼ3 (TRIB3) は,MYCを結合する新しい標的であり,主要ながん誘発因子です. TRIB3を抑制すると,MYCのレベルが効果的に低下し,様々ながんの腫瘍の成長を抑制し,新しい治療法を提供します.
科学分野
- 腫瘍学
- 分子生物学
- 薬物の発見
背景
- MYCの腫瘍性転写因子は,がんの増殖と治療抵抗性を促進する.
- MYCの大規模なインターフェースは 直接的な薬物開発を妨げています
- トリブルズシドキナーゼ3 (TRIB3) は,MYCの安定性と活動に影響を与えるMYC結合基材として特定されました.
研究 の 目的
- TRIB3-MYCの相互作用に関する構造的,生化学的,および体内のデータをレビューする.
- TRIB3-MYC軸を標的とした治療戦略を探求する.
- MYCを標的とした治療の転化課題と将来の方向性を議論する.
主な方法
- TRIB3-MYC結合に関する構造的および生化学的データの統合
- TRIB3 調節による腫瘍抑制を証明した in vivo 研究の分析
- ペプチド,小分子,PROTACを含む新たな治療方法のレビュー
主要な成果
- TRIB3の結合はMYCを安定させ,TRIB3の排除または抑制はMYCのレベルを低下させ,その腫瘍的プログラムを静止させます.
- TRIB3 に関する2つの固体腫瘍回路が詳細に示された:肺腺がんと乳がん.
- TRIB3 破壊物質を含む組み合わせ治療は,臨床前モデルにおいて,相乗効果を示しています.
結論
- TRIB3-MYCインターフェースは,直接のMYC封鎖のためのドラッグ可能なターゲットを表します.
- TRIB3を標的とした新興治療法は,MYC主導の癌に対する有望な戦略を提供します.
- 薬の投与,患者の選択,および規制の経路の進歩は,臨床翻訳を容易にする.
関連する概念動画
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

